CXCR4-Targeted Lipid-Coated PLGA Nanoparticles Deliver Sorafenib and Overcome Acquired Drug Resistance in Liver Cancer
碩士 === 國立清華大學 === 生物醫學工程研究所 === 103 === Sorafenib, a multikinase inhibitor, has been used as an anti-angiogenic agent against highly vascular hepatocellular carcinoma (HCC) – yet associated with only moderate therapeutic effect and the high incidence of HCC recurrence. We have shown intratumoral hyp...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2015
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/41760225057581130640 |